secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0000950170-24-105706
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences names Murray Abramson SVP Clinical Development, John Fry as HBV Advisor; CMO List retires
--------------------------------------------------------------------------------

- Alan List, CMO, retiring effective Sept 13, 2024; will transition to clinical consultant at $325/hour and remain on SAB.
- Murray Abramson, MD MPH, appointed SVP Head of Clinical Development; previously SVP at Tempus, VP at Biogen, roles at Merck.
- John Fry appointed Strategic Clinical Advisor for hepatitis; former EVP at Aligos Therapeutics, Head Early Development at Alios.
- Leadership changes strengthen team for PBGENE-HBV (hepatitis B) with anticipated Phase 1 data milestones in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024105706/0000950170-24-105706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024105706/dtil-20240909.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-105706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer